



(11) **EP 1 887 082 A3**

(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
11.06.2008 Bulletin 2008/24

(51) Int Cl.:
C12N 15/55 ^(2006.01) **C12Q 1/68** ^(2006.01)
C12P 21/06 ^(2006.01) **C12N 15/00** ^(2006.01)
C12N 15/09 ^(2006.01)

(43) Date of publication A2:
13.02.2008 Bulletin 2008/07

(21) Application number: **07118615.9**

(22) Date of filing: **20.10.2000**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

(30) Priority: **20.10.1999 US 421213**

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
00973739.6 / 1 226 150

(71) Applicant: **THE BOARD OF TRUSTEES OF THE
UNIVERSITY OF
ARKANSAS
Little Rock, AR 72207-3608 (US)**

(72) Inventors:
• **O'Brien, Timothy J.
Little Rock, AR 72207 (US)**
• **Tanimoto, Hirotoshi
Marugame, Kagawa 763-0033 (JP)**

(74) Representative: **McQueen, Andrew Peter
Stevens, Hewlett & Perkins
1 St. Augustine's Place
Bristol BS1 4UD (GB)**

(54) **TADG-15: An extracellular serine protease overexpressed in carcinomas**

(57) The present invention provides DNA encoding a TADG-15 protein as well as a TADG-15 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell. The present invention further provides for methods of inhibiting TADG-15 expression and/or protease activity, methods of detecting TADG-15

mRNA and/or protein and methods of screening for TADG-15 inhibitors. Additionally, the present invention provides for cell-specific targeting via TADG-15 and methods of vaccinating an individual against TADG-15. The methods described are useful in the diagnosis, treatment and prevention of cancer, particularly breast and ovarian cancer.

EP 1 887 082 A3



| DOCUMENTS CONSIDERED TO BE RELEVANT | | | |
|--|---|---|---|
| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | CLASSIFICATION OF THE APPLICATION (IPC) |
| X | WO 99/42120 A (UNIV ARKANSAS) 26 August 1999 (1999-08-26) | 1-8 | INV. C12N15/55 |
| Y | * the whole document * ----- | 1-8 | C12Q1/68 C12P21/06 |
| Y | WO 98/41656 A (UNIV ARKANSAS ; OBRIEN TIMOTHY J (US)) 24 September 1998 (1998-09-24) * the whole document * ----- | 1-8 | C12N15/00 C12N15/09 |
| Y | WO 99/36550 A (INCYTE PHARMA INC ; CORLEY NEIL C (US); YUE HENRY (US); BANDMAN OLGA () 22 July 1999 (1999-07-22) * the whole document * ----- | 1-8 | |
| Y | DUBOIS BERTRAND ET AL: "Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes" JOURNAL OF EXPERIMENTAL MEDICINE, vol. 185, no. 5, 1997, pages 941-951, XP002463008 ISSN: 0022-1007 * the whole document * ----- | 4-8 | |
| Y | MAYORDOMO J I ET AL: "BONE MARROW-DERIVED DENDRITIC CELLS PULSED WITH SYNTHETIC TUMOUR PEPTIDES ELICIT PROTECTIVE AND THERAPEUTIC ANTITUMOUR IMMUNITY" NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 1, no. 12, 1 December 1995 (1995-12-01), pages 1297-1302, XP000605402 ISSN: 1078-8956 * the whole document * ----- | 4-8 | |
| | | | TECHNICAL FIELDS SEARCHED (IPC) |
| | | | C12N C12Q |
| -The present search report has been drawn up for all claims | | | |
| Place of search Munich | | Date of completion of the search 23 April 2008 | Examiner Valcárcel, Rafael |
| CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document | | T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document | |

8
EPO FORM 1503 03.02 (P04C01)



| DOCUMENTS CONSIDERED TO BE RELEVANT | | | |
|--|---|---|---|
| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | CLASSIFICATION OF THE APPLICATION (IPC) |
| Y | NI K ET AL: "The role of dendritic cells in T cell activation" IMMUNOLOGY AND CELL BIOLOGY, vol. 75, no. 3, 1997, pages 223-230, XP009093913 ISSN: 0818-9641 * the whole document * | 4-8 | |
| Y | ----- MCARTHUR J G ET AL: "Induction of protective anti-tumor immunity by gene-modified dendritic cells." JOURNAL OF IMMUNOTHERAPY (HAGERSTOWN, MD. : 1997) JAN 1998, vol. 21, no. 1, January 1998 (1998-01), pages 41-47, XP002947331 ISSN: 1524-9557 * the whole document * | 4-8 | |
| Y | ----- LIM JONG-SEOK ET AL: "Selection of peptides that bind to the HLA-A2.1 molecule by molecular modelling" MOLECULAR IMMUNOLOGY, vol. 33, no. 2, 1996, pages 221-230, XP002477805 ISSN: 0161-5890 * the whole document * | 1-8 | |
| | | | TECHNICAL FIELDS SEARCHED (IPC) |
| ----- -/-- | | | |
| The present search report has been drawn up for all claims | | | |
| Place of search Munich | | Date of completion of the search 23 April 2008 | Examiner Valcárcel, Rafael |
| CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document | | T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document | |

EPO FORM 1503 03 82 (P04C01)



| DOCUMENTS CONSIDERED TO BE RELEVANT | | | |
|---|--|--|---|
| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | CLASSIFICATION OF THE APPLICATION (IPC) |
| Y | <p>STUBER G ET AL: "HLA-A0201 AND HLA-B7 BINDING PEPTIDES IN THE EBV-ENCODED EBNA-1, BNA-2 AND BZLF-1 PROTEINS DETECTED IN THE MHC CLASS I STABILIZATION ASSAY. LOW PROPORTION OF BINDING MOTIFS FOR SEVERAL HLA CLASS I ALLELES IN EBNA-1" INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 7, no. 4, 1995, pages 653-663, XP001147078 ISSN: 0953-8178 * the whole document *</p> <p>-----</p> | 1-8 | |
| Y | <p>LEHNER PAUL J ET AL: "Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V-beta-17 gene segment" JOURNAL OF EXPERIMENTAL MEDICINE, vol. 181, no. 1, 1995, pages 79-91, XP002477806 ISSN: 0022-1007 * the whole document *</p> <p>-----</p> | 1-8 | |
| D,Y | <p>PARKER K C ET AL: "SCHEME FOR RANKING POTENTIAL HLA-A2 BINDING PEPTIDES BASED ON INDEPENDENT BINDING OF INDIVIDUAL PEPTIDE SIDE-CHAINS" JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO, US, vol. 152, no. 1, January 1994 (1994-01), pages 163-175, XP000884375 ISSN: 0022-1767 * the whole document *</p> <p>-----</p> <p style="text-align: center;">-/--</p> | 1-8 | |
| The present search report has been drawn up for all claims | | | |
| Place of search Munich | | Date of completion of the search 23 April 2008 | Examiner Valcárcel, Rafael |
| <p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> | | <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>..... & : member of the same patent family, corresponding document</p> | |

8
EPO FORM 1503 03.02 (P04C01)



| DOCUMENTS CONSIDERED TO BE RELEVANT | | | |
|---|--|---|---|
| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | CLASSIFICATION OF THE APPLICATION (IPC) |
| Y | BRUSIC V ET AL: "A neural network model approach to the study of human TAP transporter." IN SILICO BIOLOGY 1999, vol. 1, no. 2, 4 August 1998 (1998-08-04), pages 109-121, XP009099208 ISSN: 1386-6338 The whole document. The publication date of 04-08-1998 is the one of the electronic publication. ----- | 1-8 | |
| | | | TECHNICAL FIELDS SEARCHED (IPC) |
| | | | |
| The present search report has been drawn up for all claims | | | |
| Place of search Munich | | Date of completion of the search 23 April 2008 | Examiner Valcárcel, Rafael |
| CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document | | T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document | |

8
EPO FORM 1503 03 82 (P04C01)

**CLAIMS INCURRING FEES**

The present European patent application comprised at the time of filing more than ten claims.

- Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

- All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
1-8 (all partially)
- None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:
- The present supplementary European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims (Rule 164 (1) EPC).



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

Invention 1: Claims 1-8 (all partially)

Immunogenic composition comprising SEQ ID NO: 2 (TADG-15) or an immunogenic fragment thereof not being one of SEQ ID NOS: 19, 20, 21, 29, 39, 49, 50, 59, 79, 80, 81, 82, 83, 84, 89 and 90.

Uses according to claims 4-8 of the above defined immunogenic composition.

Inventions 2-17: Claims 1-8 (all partially)

An immunogenic composition wherein the 9 residue fragment is one of SEQ ID NOS: 19, 20, 21, 29, 39, 49, 50, 59, 79, 80, 81, 82, 83, 84, 89, and 90.

Uses according to claims 4-8 of the above defined immunogenic compositions.

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 07 11 8615

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

23-04-2008

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| WO 9942120 | A | 26-08-1999 | AT 258060 T | 15-02-2004 |
| | | | AU 750932 B2 | 01-08-2002 |
| | | | AU 2869299 A | 06-09-1999 |
| | | | CA 2324993 A1 | 26-08-1999 |
| | | | DE 69914309 D1 | 26-02-2004 |
| | | | DE 69914309 T2 | 05-01-2005 |
| | | | DK 1056466 T3 | 24-05-2004 |
| | | | EP 1056466 A1 | 06-12-2000 |
| | | | ES 2215376 T3 | 01-10-2004 |
| | | | PT 1056466 T | 30-06-2004 |
| | | | US 5972616 A | 26-10-1999 |
| WO 9841656 | A | 24-09-1998 | AU 6468998 A | 12-10-1998 |
| | | | US 6303318 B1 | 16-10-2001 |
| | | | US 6316213 B1 | 13-11-2001 |
| | | | US 6294344 B1 | 25-09-2001 |
| | | | US 6268165 B1 | 31-07-2001 |
| WO 9936550 | A | 22-07-1999 | AU 2113599 A | 02-08-1999 |
| | | | CA 2317094 A1 | 22-07-1999 |
| | | | EP 1045913 A2 | 25-10-2000 |
| | | | JP 2002508970 T | 26-03-2002 |
| | | | US 6203979 B1 | 20-03-2001 |

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82